Duration and reliability of the silent period in individuals with spinal cord injury

Hannah Sfreddo[a]*, Jaclyn R. Wecht[a]*, Ola Alsalman[a,b], Yu-Kuang Wu [a,b], Noam Y. Harel [a,b]

* Contributed equally

[a], James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468

USA

[b], Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, New York

10029 USA

<u>Corresponding Author</u>:

Noam Y. Harel, MD, PhD

718-584-9000 x1742 (p); 888-299-1965 (f); noam.harel@mssm.edu

Objective: We aim to better understand the silent period (SP), an inhibitory counterpart to the

well-known motor evoked potential (MEP) elicited by transcranial magnetic stimulation (TMS), in

individuals with spinal cord injury (SCI).

Methods: Electromyographic responses were measured in the target abductor pollicis brevis at

rest (TMS at 120% of resting motor threshold (RMT)) and during maximal effort (TMS at 110%

of RMT). Participants with chronic cervical SCI (n=9) and able-bodied volunteers (n=12)

underwent between 3-7 sessions of stimulation on separate days. The primary outcomes were

the magnitude and reliability of SP duration, resting and active MEP amplitudes, and RMT.

Results: SCI participants showed significantly increased RMT, decreased MEP amplitudes, and

non-significantly longer SP duration compared to AB participants. In contrast to high inter-

participant variability, SP duration demonstrated reduced intra-participant variability within and

across sessions compared with resting and active MEP amplitudes. SCI participants also

demonstrated a higher prevalence of SP 'interruptions' compared to AB participants.

Conclusions: SP reflects a balance between corticospinal excitatory and inhibitory processes.

SP duration is more reliable within and across multiple sessions than MEP amplitude.

Significance: The higher reliability of SP duration may make it a useful outcome measure for

future trials of SCI interventions.

Highlights

1. We compared characteristics of the silent period between individuals with spinal cord injury and able-bodied volunteers.

2. Silent period duration was insignificantly longer in spinal cord injury individuals.

3. Silent period duration was found to be a more reliable within-subject metric than motor evoked potential amplitude.

Objective: We aim to better understand the silent period (SP), an inhibitory counterpart to the well-known motor evoked potential (MEP) elicited by transcranial magnetic stimulation (TMS), in individuals with spinal cord injury (SCI).

Methods: Electromyographic responses were measured in the target abductor pollicis brevis at rest (TMS at 120% of resting motor threshold (RMT)) and during maximal effort (TMS at 110% of RMT). Participants with chronic cervical SCI (n=9) and able-bodied volunteers (n=12) underwent between 3-7 sessions of stimulation on separate days. The primary outcomes were the magnitude and reliability of SP duration, resting and active MEP amplitudes, and RMT.

Results: SCI participants showed significantly increased RMT, decreased MEP amplitudes, and non-significantly longer SP duration compared to AB participants. In contrast to high inter-participant variability, SP duration demonstrated reduced intra-participant variability within and

across sessions compared with resting and active MEP amplitudes. SCI participants also

demonstrated a higher prevalence of SP 'interruptions' compared to AB participants.

Conclusions: SP reflects a balance between corticospinal excitatory and inhibitory processes.

SP duration is more reliable within and across multiple sessions than MEP amplitude.

Significance: The higher reliability of SP duration may make it a useful outcome measure for

future trials of SCI interventions.

Keywords: Transcranial magnetic stimulation, motor evoked potential, silent period, spinal cord

injury, reliability

1 Introduction

The motor evoked potential (MEP) amplitude in response to transcranial magnetic stimulation (TMS) is one of the most commonly used outcome measures for tracking neurophysiology of the corticospinal system. Spinal cord injury (SCI) reduces MEP amplitude in muscles below the injury, reflecting reduced excitatory transmission across the spinal lesion. In contrast, corticospinal inhibitory processes are comparatively understudied after SCI. The silent period (SP) occurs upon TMS administration to the contralateral motor cortex during volitional contraction of the target muscle. The resulting MEP is followed by a brief period of electromyographic (EMG) suppression (silent period) usually lasting 100-300 milliseconds [1–4] (Figure 1).

Spinal inhibitory mechanisms contribute to the first ~50 ms of the SP through segmental recurrent inhibition of motor neurons [1,3]. Intracortical gamma-aminobutyric acid $(GABA)_B$ receptors that mediate inhibitory feedback onto pyramidal motor cortex neurons play a major role in mediating the remainder of the SP [2,5]. This is most clearly demonstrated by the elongation of SP duration when baclofen, a specific $GABA_B$ receptor agonist, is delivered intrathecally [6,7]. However, studies of oral and intravenous baclofen have failed to demonstrate a significant effect on SP duration [5,8,9].

Lesions of the nervous system may lengthen or shorten SP duration. Cerebral pathologies that lengthen SP include stroke [10–12], epilepsy [13,14], and depression [15]. Conversely, pathologies that

shorten SP include unmedicated schizophrenia [16], bipolar disorder [17], and chronic neuropathic

pain [18].

Few prior studies have investigated SP in the SCI population, with mixed results [8,19–22]. It is not

yet fully elucidated whether SCI lengthens SP (perhaps due to decreased afferent feedback

from the periphery onto cortical GABAergic interneurons) or shortens SP (perhaps due to

increased cortical or spinal segmental excitability). Furthermore, the relative reliability of SP

duration as an outcome metric in SCI relative to the more commonly used MEP amplitude is

hardly known [23]. Therefore, we compared magnitude and variability of hand muscle SP

durations, MEP thresholds, and MEP amplitudes in individuals with chronic cervical SCI and

able-bodied volunteers across multiple testing sessions.

2 Methods

2.1 Design – This experiment was an exploratory portion of a larger study in which we tested a

novel configuration for non-invasive cervical transcutaneous spinal stimulation (clinicaltrials.gov

NCT02469675) [24]. All procedures were approved by the Institutional Review Board of the James

J. Peters VA Medical Center, Bronx, NY. All applicable institutional and governmental

regulations concerning the ethical participation of human volunteers were followed during this

research.

2.3 General Procedure – Neurological examination was performed according to the

International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI).

Sessions were performed on separate days at a consistent time of day per participant, with

attempts to maintain consistent quantity and timing of caffeine intake. Stimulation was delivered

with participants in a seated upright position in an adjustable TMS treatment chair (Magventure),

or for one participant, in her own wheelchair. For participants without neurological injury, TMS

was targeted toward the dominant hand. For those with SCI, TMS was targeted toward the hand

with lower motor thresholds and more reliable electrophysiological responses. Arms and hands

were pronated and relaxed on a cushion placed in the participant's lap.

2.4 Transcranial Magnetic Stimulation (TMS) – A MagPro R30 or X100 system (Magventure)

with 80mm winged coil (D-B80) was used. The magnet was oriented at a 45-degree angle from

the sagittal plane, centered over the hand motor cortex hotspot for maximal APB response. The

first 11 participants wore reusable cloth headcaps upon which the hotspot was labeled with a

marker in relation to the vertex. Our laboratory obtained an optical infrared tracking system

(Northern Digital Polaris) integrated with a Brainsight neural navigation system (Rogue

Research) that was used to track hotspots from participant 12 and onward. RMT was

determined as the percent of maximal stimulator output required to elicit an MEP in the APB

muscle of at least 50 µV in 5 out of 10 repetitions.

2.5 Electromyographic Data – EMG of the target APB was recorded using surface sensors

with 300x preamplification, 15-2,000 Hz bandwidth, and internal grounding (Motion Lab Systems

Z03-002). EMG was collected at a sample rate of 5,000 Hz via digital acquisition board and

customized LabVIEW software (National Instruments USB-6363). All EMG data were acquired

and quantified using custom LabVIEW scripts.

2.6 Eliciting and Measuring the Silent Period (SP) – While participants pinched a

dynamometer between their thumb and third finger using maximal effort, a single TMS pulse

was delivered over the hand motor cortex hotspot at 110% of each participant's RMT. The

resulting MEP amplitude and SP duration in the contralateral APB muscle were measured. Five

to six replicates were performed per session. Participants completed a total of 7 sessions on

different days involving SP, apart from three individuals who withdrew from the study before

completion.

To quantify SP_{DUR}, SP onset was visually defined as the end of the TMS-induced MEP, and SP

offset was defined as the earliest resumption of pre-TMS EMG activity [25,26] (Figure 1).

We defined an "SP interruption" as a spike in EMG activity surrounded by SP silence, where the

duration of interruption was less than 20 ms, and the absolute amplitude from one peak to the

adjacent trough was at least 25% of the largest amplitude found during the 100 ms preceding

the TMS impulse.

2.7 Analysis – <u>Outcomes</u>: The primary dependent variables were MEP amplitude (mV) at rest

(MEP_{REST}) and during SP elicitation (MEP_{ACTIVE}), SP duration (ms) (SP_{DUR}), and RMT (%

maximum stimulator output). SP interruptions were an exploratory outcome. For each

participant, within-session means were computed from the 5-6 replicates of each test, then

averaged across sessions. Before group comparisons, each outcome was first tested for

normality using the Shapiro-Wilks test. Normally distributed values (MEP_{ACTIVE}, SP_{DUR}, and

RMT) were compared between AB and SCI groups using independent-sample t-tests. Non-

normally distributed values (MEP_{REST}) were compared using an independent-samples Mann-

Whitney U test.

<u>Correlations</u>: Bivariate correlations were assessed between the primary dependent variables

(MEP_{REST}, MEP_{ACTIVE}, SP_{DUR}, and RMT) for each group. Pearson correlations were applied for

normally distributed values, whereas Spearman's rho test was applied for non-normally

distributed values.

<u>Variability</u>: Within-session coefficients of variation (CV) were computed for each participant from

the 5-6 replicates of each test, then averaged across sessions. Note that RMT was only

determined once per session, so it was not possible to determine within-session RMT variability.

Between-session CVs were computed from the session means of each test. CVs were then

averaged across participants within each group. As CV values were not normally distributed, the

non-parametric related-samples Friedman's two-way analysis of variance by ranks test was

applied to compare CVs across outcomes within each group. Significant values on Friedman's

test were analyzed post-hoc between pairs of outcomes using related-samples Wilcoxon signed

rank tests.

<u>Interruptions</u>: A chi-squared test was used to compare the frequency of participants with

interrupted SPs between groups. As interruption values were not normally distributed, the non-

parametric Mann-Whitney U test was used to compare number of interruptions per participant

between groups.

Excel (Microsoft) and SPSS Version 25 (IBM) were used for all analyses.

Individual-level data is included as Supplementary Data 1 (by participant, averaged across

sessions) and Supplementary Data 2 (by participant per session).

3 Results

3.1 Participants – 21 individuals (12 AB and 9 SCI; 17 males, 4 females) participated in this

study (Table 1). Participants ranged in age from 22 to 64 years old. Of the 9 SCI participants,

eight had traumatic SCI, one had idiopathic transverse myelitis.

Table 1A – SCI Demographics

ID	Gender	Age	Etiology of Injury	DOI (Years)	LOI	ISNCSCI Grade	TMS Threshold (% MSO)
1	M	29	T	3	C8	C	45.9
2	M	52	T	17	C8	C	35.8

18	M	64	T	14	C4	D	59.4
23	M	57	T	12	C4	D	60.8
27	M	40	T	14	C4	D	69.7
28	M	42	T	16	C5	D	65.9
31	M	54	T	6	C5	C	52.7
34	F	52	T	16	C4	B	72.0
39	F	22	NT	1	C5	C	30.0
Totals	7M, 2F	45.8 (22-64)	8T, 1NT	11 (1-17)	C4-C8	1B, 4C, 4D	54.7 (30.0-72.0)

190   **Table 1B – AB Demographics**

ID	Gender	Age	TMS Threshold (% MSO)
5	M	25	35.1
8	M	27	34.1
9	M	44	35.9
11	F	22	38.2
12	F	23	30.6
14	M	44	32.6
15	M	45	44.4
16	M	24	52.3

22	M	58	53.9
25	M	55	41.9
36	M	23	32.6
38	M	22	53.0
Totals	**10M, 2F**	**34.3 (22-58)**	**40.4 (30.6-53.9)**

Table 1. Participant demographics. A) SCI. Etiology of Injury – traumatic (T) or not traumatic

(NT); DOI – duration of injury; LOI – neurological level of injury; ISNCSCI – International

Standards for the Neurological Classification of SCI; %MSO – percent of maximal stimulator

output. **B) AB**.

3.2 SP duration – SCI participants showed non-significantly longer SPs (111.40 ± 18.39 ms;

range 46.90 – 216.17 ms) than AB participants (97.99 ± 9.88 ms; range 35.30 – 152.86 ms)

(non-significant, independent-sample t-test) (Table 2).

3.3 Resting motor threshold – SCI participants showed significantly higher RMTs (54.69 ±

4.94% maximum stimulator output; range 30.0 – 72.0) than AB participants (40.37 ± 2.48%

maximum stimulator output, range 30.6 – 53.9) (p=0.012, independent-sample t-test) (Table 2).

3.4 MEP amplitudes – SCI participants showed significantly lower MEP_{REST} amplitudes (0.148

± 0.018 mV) than AB participants (0.462 ± 0.094 mV) (p<0.0005 independent-samples Mann-

Whitney U test). SCI participants showed significantly lower MEP_{ACTIVE} amplitudes (0.700 ±

0.133 mV) than AB participants (2.305 ± 0.233 mV) (p<0.0005 independent-sample t-test)

(Table 2).

 Table 2

Outcome	AB (n=12)	SCI (n=9)
RMT (% MSO) *	**40.37** (2.48)	**54.69** (4.94)
SP$_{DUR}$ (ms)	**97.99** (9.88)	**111.4** (18.39)
MEP$_{REST}$ (mV)*	**0.462** (0.094)	**0.148** (0.018)
MEP$_{ACTIVE}$ (mV) *	**2.305** (0.233)	**0.700** (0.133)

Table 2 – Between-group comparisons. Means across sessions (S.E.M.). RMT, resting motor

threshold. % MSO, percent maximum stimulator output. SP$_{DUR}$, SP duration. ms, milliseconds.

MEP$_{REST}$, amplitude of resting motor evoked potential. mV, millivolts. MEP$_{ACTIVE}$, amplitude of

active motor evoked potential. *, statistically significant between-group difference.

3.5 Correlations – In AB participants, SP duration was inversely correlated with MEP$_{REST}$

amplitudes (Spearman's rho -0.790, p=0.002), with a tendency toward inverse correlation with

MEP$_{ACTIVE}$ amplitudes (Pearson correlation -0.547, p=0.065). In SCI participants, SP duration

was not significantly correlated with MEP amplitudes (Pearson correlation 0.072 for MEP$_{REST}$

amplitude, -0.202 for MEP$_{ACTIVE}$ amplitude).

3.6 Intraindividual variability within sessions (Table 3, Figure 2A) – In AB volunteers, the

within-session CV was 13.05 ± 1.40 for SP$_{DUR}$, 59.79 ± 4.49 for MEP$_{REST}$, and 21.83 ± 1.78 for

MEP$_{ACTIVE}$ (p<0.0005 on related-samples Friedman's two-way analysis of variance by ranks

test). Post hoc pairwise comparisons showed that SP$_{DUR}$ had significantly lower within-session

CV than both MEP$_{REST}$ (p=0.002 on related-samples Wilcoxon signed rank test) and MEP$_{ACTIVE}$

(p=0.005 on related-samples Wilcoxon signed rank test). In SCI participants, the CV was 16.08

± 2.56 for SP$_{DUR}$, 52.93 ± 6.18 for MEP$_{REST}$, and 28.38 ± 2.64 for MEP$_{ACTIVE}$ (p<0.0005 on

related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise

comparisons showed that SP$_{DUR}$ had significantly lower within-session CV than both MEP$_{REST}$

(p=0.008 on related-samples Wilcoxon signed rank test) and MEP$_{ACTIVE}$ (p=0.028 on related-

samples Wilcoxon signed rank test). Thus, SP$_{DUR}$ has lower within-session variability than MEP

amplitudes in both able-bodied and SCI individuals.

Table 3

Outcome	Group	Within-session	Between-session
RMT	AB		**6.96** (0.69)
	SCI		**9.19** (1.21)
SP$_{DUR}$	AB	**13.05** (1.40)	**19.61** (2.67) ‡
	SCI	**16.08** (2.56)	**28.50** (5.30) ‡
MEP$_{REST}$	AB	**59.79** (4.49) *	**52.04** (6.32) *‡

	SCI	**52.93** (6.18) *	**45.08** (6.90) ‡
MEP$_{ACTIVE}$	AB	**21.83** (1.78) *	**33.58** (4.12) *‡
	SCI	**28.38** (2.64) *	**35.06** (3.63) ‡

Table 3 – Outcome variability. Coefficients of variation (S.E.M.) for AB and SCI groups. *****, statistically significant difference between SP$_{DUR}$ and other outcomes within each group. **‡**, statistically significant difference between RMT and other outcomes within each group.

3.7 Intraindividual variability across sessions (Table 3, Figure 2B) – In AB volunteers, the between-session CV was 19.61 ± 2.67 for SP$_{DUR}$, 52.04 ± 6.32 for MEP$_{REST}$, 33.58 ± 4.12 for MEP$_{ACTIVE}$, and 6.96 ± 0.69 for RMT ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP$_{DUR}$ had significantly lower between-session CV than both MEP$_{REST}$ ($p=0.002$ on related-samples Wilcoxon signed rank test) and MEP$_{ACTIVE}$ ($p=0.019$ on related-samples Wilcoxon signed rank test), but significantly higher between-session CV than RMT ($p=0.004$ on related-samples Wilcoxon signed rank test). In SCI participants, the CV was 28.50 ± 5.30 for SP$_{DUR}$, 45.08 ± 6.90 for MEP$_{REST}$, 35.06 ± 3.63 for MEP$_{ACTIVE}$, and 9.19 ± 1.21 for RMT ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP$_{DUR}$ had a non-significant trend toward lower between-session CV than MEP$_{REST}$ ($p=0.086$ on related-samples Wilcoxon signed rank test), and no significant difference from MEP$_{ACTIVE}$ ($p=0.314$ on related-samples Wilcoxon signed rank test). As in AB participants,

SP$_{DUR}$ had significantly higher between-session CV than RMT (p=0.015 on related-samples

Wilcoxon signed rank test) in SCI participants. Thus, SP$_{DUR}$ had significantly lower between-

session variability than MEP amplitudes in able-bodied but not SCI individuals. However, RMT

values were clearly more reliable across sessions than SP duration or MEP amplitudes.

3.8 SP Interruptions – 3 out of 12 AB participants and 8 out of 9 SCI participants showed

interrupted SPs (p =0.004; Pearson chi-square test). Per session, AB volunteers showed 0.089

± 0.71 interruptions, while SCI volunteers showed 1.781 ± 0.787 interruptions (p=0.001 on

independent-samples Mann-Whitney U test) (Figure 3). From the perspective of individual SP

trials, there were five interrupted CSPs out of 467 total CSP events (1.07%) in AB participants,

and 52 interrupted CSPs out of 242 total CSP events (21.5%) in SCI participants.

4 Discussion

The current study measured corticospinal excitatory-inhibitory balance as reflected by

MEP amplitude and SP duration in individuals with and without SCI. Our data confirm the well-

known finding that SCI individuals have higher TMS motor thresholds and lower MEP

amplitudes than able-bodied volunteers, indicating reduced excitability of the motor cortex,

reduced corticospinal transmission, reduced excitability of local spinal circuitry, or any

combination thereof. Due to large variability *between* individuals, we found no significant

difference in SP duration between SCI and able-bodied participants. Importantly, relative

variability *within* individuals of SP duration is lower than variability of MEP amplitude, suggesting

that SP duration may be a useful outcome measure with higher signal-to-noise ratio.

Appropriate movement requires inhibitory neural feedback as well as neural excitation

[27,28]. Consequently, imbalance between neural excitation and inhibition may contribute to the

failure in restoration of useful motor function after SCI [29]. Whereas MEP amplitude represents a

straightforward excitatory readout, the relationship between clinical symptoms, disease entities,

and neurophysiological inhibitory pathways as reflected by SP duration is more complex. A

prolonged SP has been reported in a number of cerebral pathologies such as stroke [10–12,]

spinocerebellar ataxia [30], sport-related concussion [31], epilepsy [13,14], Huntington's disease [32], and

depression [15]. On the other hand, shortened SP duration has been reported in unmedicated

schizophrenia [16], bipolar disorder [17], obsessive compulsive disorder [33], writer's cramp [34],

Parkinson's [35], Alzheimer's diseases [36], fibromyalgia [37], and chronic neuropathic pain [18].

Thus, lesions affecting the cortex, corticospinal tract, or segmental spinal circuits may

affect SP duration in opposing fashion. Further complicating the interpretation of SP duration, a

variety of experimental factors affect SP. In our study, we examined SP duration in the context

of a maximal-effort pincer grip between the thumb and third finger, with a relatively low TMS

intensity (110% of RMT). SP duration correlates positively with increases in TMS intensity, but

does not correlate with level of volitional contraction [3,11,38,39]. SP duration is also highly task

dependent. In young adults, the fractionated task of abducting the index finger demonstrated

longer SP duration than a task involving pincer grip between the thumb and index finger, which

demonstrated longer SP duration than a task involving power grip [40]. This suggests an inverse

correlation between SP duration and the number of muscles used for a task. Another study in

healthy adults showed that increasing amounts of sensory afferent input shortened SP duration

[41]. These studies demonstrated the importance of afferent feedback in downwardly modulating

SP duration, presumably by inhibiting the cortical GABAergic interneurons that mediate SP [20].

Thus, SCI would be expected to prolong SP duration due to reduced afferent feedback through

the lesioned cord.

Our study did not show a significant difference in SP duration between SCI and AB

participants. We speculate that the relatively low TMS intensity used in our study contributed to

shorter SP duration and increased variability between individuals, reducing sensitivity to detect

differences [26,42]. Prior investigation of SP in the SCI population has been limited. In six

participants after thoracolumbar SCI, SP duration in hand muscles above the lesion increased

(APB muscle, "gentle" pincer effort; TMS intensity at 140-180% RMT), MEP amplitudes

decreased, and cortical motor map representations shifted [19]. The altered cortical maps in this

study, as well as the observed changes in muscles rostral to the spinal lesion level, suggested

that these neurophysiological changes after SCI were cortical in origin.

Likewise, a study of 16 participants with chronic cervical SCI relative to 18 uninjured

controls showed prolonged SP duration (FDI muscle, 25% effort, TMS intensity set to produce

similar MEP amplitude across participants) after SCI, regardless of oral baclofen intake [8]. The

difference in SP duration seen by Barry and colleagues was observed when evoked by TMS but

not when evoked by transcranial electrical stimulation (TES) – since TMS activates corticospinal

neurons indirectly through cortical interneurons, this discrepancy between TMS and TES

pointed to cortical mechanisms for SP elongation after SCI. A study of nine males with chronic

cervical SCI observed prolonged SP (extensor digitalis communis muscle, 10% effort, TMS

intensity at 110% AMT), increased motor thresholds, and shifted cortical maps relative to

uninjured controls [21]. Participants with greater spinal cord atrophy in that study showed relatively

greater changes in SP and motor thresholds, suggesting that corticospinal transmission and

local cord circuitry contributed to the observed neurophysiological changes.

On the contrary, a study of three individuals with cervical SCI showed loss of SP in two

of three hand muscles and all three foot muscles (50% effort, TMS intensity at 100% of

stimulator output) [22]. The authors speculated that SP loss derived from abnormal ascending

sensory activity leading to cortical hyperexcitability, and/or increased local spinal neuronal

excitability.

Our findings of decreased coefficients of variation in SP duration relative to MEP

amplitude support the contention that SP duration may be a more reliable TMS metric than MEP

amplitude. One other study measured MEPs and SP across time in individuals with chronic

incomplete tetraplegia [23]. In that study, SP duration had relatively high reliability for both

stronger and weaker muscles, whereas MEP amplitude had medium reliability for stronger

muscles and poor reliability for weaker muscles. Studies in able-bodied participants provide

further evidence that SP duration is more reliable across sessions than across individuals [11,42].

Importantly, resting motor threshold, which is determined at the beginning of any experimental

TMS session, showed the least between-session variability of the measures we examined. It

remains to be determined whether motor threshold is more sensitive than other measures to

detecting changes after interventions aimed to increase central neural transmission.

Our observation that SP duration in able-bodied participants tended to inversely

correlate with MEP amplitude conflicts with the findings of Orth and Rothwell, who found a

strong positive correlation [42]. In that study, SP was determined in the FDI muscle at 20% effort

across a range of TMS intensities, whereas our study assessed the APB muscle at maximal

effort at low TMS intensity. Our observation that SP duration and MEP amplitude did not

correlate in SCI participants suggests disruption of the delicate balance between excitatory and

inhibitory pathways.

We observed an overwhelmingly higher prevalence of SP 'interruption' frequency in SCI

relative to AB participants. The simplest explanation for these spikes in EMG activity within SPs

is that these are fasciculations of individual motor units. Fasciculations represent spontaneous

hyperexcitable discharges more often seen in individuals with lower motor neuron degeneration

and injury, usually arising from the distal axons of lower motor neurons, and thus are less likely

to be silenced by TMS [43,44]. Many individuals with chronic cervical SCI display frequent

fasciculations in muscles innervated from the level of injury. Therefore, it is not surprising that

SCI participants demonstrated a much higher SP interruption rate than AB participants.

Our study has several important limitations: The SCI group was older than the control

group. Individuals in the SCI group were more likely to be taking oral baclofen or other neural

inhibitory medications. However, oral baclofen has not clearly been shown to affect SP duration

[45]. TMS intensity during SP measurements was at 110% of resting motor threshold – most

studies have used higher TMS intensities, which is a key factor in longer SP duration and may

reduce intersession variability [26]. Post hoc statistical analyses were not corrected for multiple

comparisons.

Conclusion

In individuals with chronic cervical SCI relative to able-bodied controls, we confirmed the

well-known findings that SCI individuals have higher TMS motor thresholds and lower TMS

evoked potential amplitudes. We also observed non-significantly longer SP duration in SCI

individuals. Importantly, we observed significantly lower within-person variability of SP duration

than within-person variability of TMS response amplitude, suggesting that SP duration may be a

useful outcome measure with higher signal-to-noise ratio. Ongoing studies in our lab will further

correlate EMG with electroencephalographic features to shed more mechanistic insight into

these phenomena.

CONFLICTS OF INTEREST

The investigators have no conflicts of interest to declare.

SOURCES OF FUNDING

New York State Department of Health C30599.

References

1.   Fuhr P, Agostino R, Hallett M. Spinal motor neuron excitability during the silent period

after cortical stimulation. Electroencephalogr Clin Neurophysiol Evoked Potentials.

1991;81(4):257–62.

2.   Poston B, Kukke SN, Paine RW, Francis S, Hallett M. Cortical silent period duration and

its implications for surround inhibition of a hand muscle. Eur J Neurosci. 2012

Oct;36(7):2964–71.

3.   Inghilleri M, Berardelli A, Cruccu G, Manfredi M. Silent period evoked by transcranial

stimulation of the human cortex and cervicomedullary junction. J Physiol [Internet]. 1993

Jul [cited 2018 Apr 15];466(1):521–34. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/8410704

4.   Wu L, Goto Y, Taniwaki T, Kinukawa N, Tobimatsu S. Different patterns of excitation and

inhibition of the small hand and forearm muscles from magnetic brain stimulation in

humans. Clin Neurophysiol. 2002;113(8):1286–94.

5.   Inghilleri M, Berardelli A, Marchetti P, Manfredi M. Effects of diazepam, baclofen and

thiopental on the silent period evoked by transcranial magnetic stimulation in humans.

Exp Brain Res. 1996;109(3):467–72.

6.   Siebner HR, Dressnandt J, Auer C, Conrad B. Continuous intrathecal baclofen infusions

induced a marked increase of the transcranially evoked silent period in a patient with

generalized dystonia. Muscle and Nerve. 1998 Sep;21(9):1209–12.

7.   Stetkarova I, Kofler M. Differential effect of baclofen on cortical and spinal inhibitory

circuits. Clin Neurophysiol [Internet]. 2013 Feb [cited 2020 Apr 15];124(2):339–45.

Available from: http://www.ncbi.nlm.nih.gov/pubmed/22877625

8. Barry MD, Bunday KL, Chen R, Perez MA. Selective effects of baclofen on use-

dependent modulation of GABAB inhibition after tetraplegia. J Neurosci [Internet]. 2013

Jul 31 [cited 2014 Aug 9];33(31):12898–907. Available from:

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3728695&tool=pmcentrez&ren

dertype=abstract

9. McDonnell MN, Orekhov Y, Ziemann U. The role of GABAB receptors in intracortical

inhibition in the human motor cortex. Exp Brain Res. 2006 Aug 18;173(1):86–93.

10. Braune HJ, Fritz C. Transcranial magnetic stimulation-evoked inhibition of voluntary

muscle activity (silent period) is impaired in patients with ischemic hemispheric lesion.

Stroke. 1995;26(4):550–3.

11. Kukowski B, Haug B. Quantitative evaluation of the silent period, evoked by transcranial

magnetic stimulation during sustained muscle contraction, in normal man and in patients

with stroke. Electromyogr Clin Neurophysiol. 1992;32(7–8):373–8.

12. Gray WA, Palmer JA, Wolf SL, Borich MR. Abnormal EEG Responses to TMS during the

Cortical Silent Period Are Associated with Hand Function in Chronic Stroke. Neurorehabil

Neural Repair. 2017;31(7):666–76.

13. Ertaş NK, Gül G, Altunhalka A, Kirbas D. Cortical silent period following transcranial

magnetic stimulation in epileptic patients. Epileptic Disord [Internet]. 2000 Sep [cited 2020

Apr 3];2(3):137–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11022138

14. Macdonell RA, King MA, Newton MR, Curatolo JM, Reutens DC, Berkovic SF. Prolonged

cortical silent period after transcranial magnetic stimulation in generalized epilepsy.

Neurology [Internet]. 2001 Aug 28 [cited 2020 May 17];57(4):706–8. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/11524485

15.   Steele JD, Glabus MF, Shajahan PM, Ebmeier KP. Increased cortical inhibition in

depression: A prolonged silent period with transcranial magnetic stimulation (TMS).

Psychol Med. 2000;30(3):565–70.

16.   Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S. Evidence

for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation.

Arch Gen Psychiatry. 2002;59(4):347–54.

17.   Levinson AJ, Young LT, Fitzgerald PB, Daskalakis ZJ. Cortical inhibitory dysfunction in

bipolar disorder: A study using transcranial magnetic stimulation. J Clin

Psychopharmacol. 2007 Oct;27(5):493–7.

18.   Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex

rTMS restores defective intracortical inhibition in chronic neuropathic pain. Neurology.

2006 Nov;67(9):1568–74.

19.   Lotze M, Laubis-Herrmann U, Topka H. Combination of TMS and fMRI reveals a specific

pattern of reorganization in M1 in patients after complete spinal cord injury. Restor Neurol

Neurosci [Internet]. 2006/05/25. 2006;24(2):97–107. Available from:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation

&list_uids=16720945

20.   Nardone R, Golaszewski S, Bergmann J, Venturi A, Prünster I, Bratti A, et al. Motor

cortex excitability changes following a lesion in the posterior columns of the cervical

spinal cord. Neurosci Lett. 2008 Mar 21;434(1):119–23.

21.   Freund P, Rothwell JC, Craggs M, Thompson AJ, Bestmann S. Corticomotor

representation to a human forearm muscle changes following cervical spinal cord injury.

Eur J Neurosci [Internet]. 2011;34:1–8. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/22082003

22.   Shimizu T, Hino T, Komori T, Hirai S. Loss of the muscle silent period evoked by

transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions.

Neurosci Lett. 2000 Jun 9;286(3):199–202.

23.   Potter-Baker KA, Janini DP, Frost FS, Chabra P, Varnerin N, Cunningham DA, et al.

Reliability of TMS metrics in patients with chronic incomplete spinal cord injury. Spinal

Cord [Internet]. 2016 Apr 5 [cited 2016 Apr 10];54(11):980–90. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/27045553

24.   Wu Y-K, Levine JM, Wecht JR, Maher MT, LiMonta JM, Saeed S, et al. Posteroanterior

cervical transcutaneous spinal stimulation targets ventral and dorsal nerve roots. Clin

Neurophysiol International Federation of Clinical Neurophysiology [Internet]. 2020 Dec 13

[cited 2019 Dec 31];131(2):451–60. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/31887616

25.   Ridding MC, Rothwell JC, Inzelberg R. Changes in excitability of motor cortical circuitry in

patients with parkinson's disease. Ann Neurol. 1995;37(2):181–8.

26.   Damron LA, Dearth DJ, Hoffman RL, Clark BC. Quantification of the corticospinal silent

period evoked via transcranial magnetic stimulation. J Neurosci Methods. 2008 Aug

15;173(1):121–8.

27.   Azim E, Fink AJP, Jessell TM. Internal and external feedback circuits for skilled forelimb

movement. Cold Spring Harb Symp Quant Biol. 2014;79:81–92.

28.   Nichols TR. Distributed force feedback in the spinal cord and the regulation of limb

mechanics. Vol. 119, Journal of Neurophysiology. American Physiological Society; 2018.

p. 1186–200.

29.   Davey NJ. Responses of thenar muscles to transcranial magnetic stimulation of the motor

cortex in patients with incomplete spinal cord injury. J Neurol Neurosurg Psychiatry.

1998;65(1):80–7.

30.   Teo JTH, Schneider SA, Cheeran BJ, Fernandez-del-Olmo M, Giunti P, Rothwell JC, et

al. Prolonged cortical silent period but normal sensorimotor plasticity in spinocerebellar

ataxia 6. Mov Disord. 2008 Feb 15;23(3):378–85.

31.   Tremblay S, De Beaumont L, Lassonde M, Théoret H. Evidence for the specificity of

intracortical inhibitory dysfunction in asymptomatic concussed athletes. J Neurotrauma.

2011 Apr 1;28(4):493–502.

32.   Modugno N, Currà A, Giovannelli M, Priori A, Squitieri F, Ruggieri S, et al. The prolonged

cortical silent period in patients with Huntington's disease. Clin Neurophysiol.

2001;112(8):1470–4.

33.   Richter MA, De Jesus DR, Hoppenbrouwers S, Daigle M, Deluce J, Ravindran LN, et al.

Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive

disorder. Neuropsychopharmacology. 2012 Apr;37(5):1144–51.

34.   Tinazzi M, Farina S, Edwards M, Moretto G, Restivo D, Fiaschi A, et al. Task-specific

impairment of motor cortical excitation and inhibition in patients with writer's cramp.

Neurosci Lett. 2005 Apr 11;378(1):55–8.

35. Nakashima K, Wang Y, Shimoda M, Sakuma K, Takahashi K. Shortened silent period

produced by magnetic cortical stimulation in patients with Parkinson's disease. J Neurol

Sci. 1995;130(2):209–14.

36. Alagona G, Bella R, Ferri R, Carnemolla A, Pappalardo A, Costanzo E, et al. Transcranial

magnetic stimulation in Alzheimer disease: Motor cortex excitability and cognitive

severity. Neurosci Lett. 2001 Nov 13;314(1–2):57–60.

37. Salerno A, Thomas E, Olive P, Blotman F, Picot MC, Georgesco M. Motor cortical

dysfunction disclosed by single and double magnetic stimulation in patients with

fibromyalgia. Clin Neurophysiol. 2000 Jun 1;111(6):994–1001.

38. Triggs WJ, Macdonell RAL, Cros D, Chiappa KH, Shahani BT, Day BJ. Motor inhibition

and excitation are independent effects of magnetic cortical stimulation. Ann Neurol.

1992;32(3):345–51.

39. Kojima S, Onishi H, Sugawara K, Kirimoto H, Suzuki M, Tamaki H. Modulation of the

cortical silent period elicited by single- and paired-pulse transcranial magnetic stimulation.

BMC Neurosci. 2013 Apr 2;14.

40. Tinazzi M, Farina S, Tamburin S, Facchini S, Fiaschi A, Restivo D, et al. Task-dependent

modulation of excitatory and inhibitory functions within the human primary motor cortex.

Exp Brain Res [Internet]. 2003 May [cited 2020 Mar 22];150(2):222–9. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/12677319

41. Hess A, Kunesch E, Classen J, Hoeppner J, Stefan K, Benecke R. Task-dependent

modulation of inhibitory actions within the primary motor cortex. Exp Brain Res.

1999;124(3):321–30.

42. Orth M, Rothwell JC. The cortical silent period: Intrinsic variability and relation to the

waveform of the transcranial magnetic stimulation pulse. Clin Neurophysiol [Internet].

2004 May [cited 2020 Mar 28];115(5):1076–82. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/15066533

43. Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve [Internet].

1994 Nov 1 [cited 2020 May 24];17(11):1243–9. Available from:

http://doi.wiley.com/10.1002/mus.880171102

44. Grapperon AM, Attarian S. Disorders of motor neurons manifested by hyperactivity. Vol.

173, Revue Neurologique. Elsevier Masson SAS; 2017. p. 345–51.

45. Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy R, et al. TMS and

drugs revisited 2014. Vol. 126, Clinical Neurophysiology. Elsevier Ireland Ltd; 2015. p.

1847–68.

 Legends

Figure 1 – Schematic and examples of silent period. A) TMS is delivered (red line) to the

hand motor cortex while the participant performs a volitional isometric pinch with the

contralateral hand. The resulting MEP (black arrow) is followed by an EMG silent period before

the resumption of baseline volitional EMG activity. **B) Representative silent period in able-**

bodied volunteer. C) Representative silent period in SCI participant. APB, abductor pollicis

brevis.

Figure 2 – Outcome variability. A) Within-session coefficient of variation for each group. **B)**

Between-session coefficient of variation for each group. Error bars represent S.E.M. *,

significantly different from SP duration; ‡, significantly different from RMT.

Figure 3 – SP interruptions by group and participant. The average number of interruptions

per session for each participant. Error bars represent S.D.

Supplementary Data 1 – Participant-level data averaged across sessions.

InterssNum, number of interruptions per session; CVSPdurIntra, intrasession coefficient of

variation for SP_{DUR}; CVMEPrestIntra, intrasession coefficient of variation for MEP_{REST};

CVMEPactiveIntra, intrasession coefficient of variation for MEP_{ACTIVE}; CVRMTInter, intersession

coefficient of variation for RMT; CVSPdurInter, intersession coefficient of variation for SP_{DUR};

CVMEPrestInter, intersession coefficient of variation for MEP_{REST}; CVMEPactiveInter,

intersession coefficient of variation for MEP_{ACTIVE}.

Supplementary Data 2 – Participant-level data listed per session.

A

TMS

APB
sEMG

| EMG Activity | EMG Silence (SP) | EMG Activity Resumes |

B

C